Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495427 | 1.00 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL2765105 | 1.00 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL5492303 | 0.85 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19 | |
| SCHEMBL2763988 | 0.85 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19 | |
| SCHEMBL2763985 | 0.85 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19 | |
| SCHEMBL2764432 | 0.85 | ADAMTS5 (0.72) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL2763922 | 0.85 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL5490600 | 0.85 | ADAMTS5 (0.72) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL2763926 | 0.85 | ADAMTS5 (0.66) | ADAMTS5MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL2764429 | 0.85 | ADAMTS5 (0.72) | ADAMTS5MAPK1CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | claimed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | claimed |
| JP-2007516982-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | claimed |
| EP-1694410-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | claimed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1694410-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2135/4885CYP2C19 158/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2090/4885CYP2C19 159/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2090/4885CYP2C19 159/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | ADAMTS5 38/4885MAPK1 2078/4885CYP2C19 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.